Date: 2016-01-26
Type of information: Milestone
Compound: anetumab ravtansine (BAY 94-9343)
Company: MorphoSys (Germany) Bayer (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: milestone
Action mechanism: antibody drug conjugate. Anetumab ravtansine is an antibody-drug conjugate (ADC) targeting mesothelin. This ADC has been developed by Bayer using MorphoSys's HuCAL technology.
Disease: mesothelioma
Details:
Financial terms:
Latest news:
- • On July 21, 2017, MorphoSys announced that its partner Bayer has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural mesothelioma did not meet the primary endpoint of progression-free survival.
- Bayer reported further that, anetumab ravtansine is currently being investigated, as monotherapy and in combination, in additional studies, including a Phase Ib multi-indication study in six different types of advanced solid tumors, as well as a Phase Ib combination-study in patients with recurrent platinum-resistant ovarian cancer. According to Bayer, based on the available data, Bayer remains committed to further evaluating the utility and safety of anetumab ravtansine across multiple tumor types with significant unmet medical need.
- • On January 26, 2016, MorphoSys announced that the company earned a milestone payment with Bayer's initiation of a global phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343). Further financial details were not disclosed. MorphoSys's collaboration with Bayer has resulted in two clinical programs to date. In total, MorphoSys's partnered and proprietary clinical pipeline currently comprises 25 unique antibody molecules which are currently being evaluated in more than 50 clinical trials.
Is general: Yes
